Novel Prognostic Model Predictive of Survival in Ibrutinib-Treated Chronic Lymphocytic Leukemia
Researchers evaluated and validated the effectiveness of a 4-factor prognostic model among patients with CLL treated with ibrutinib.
Chronic Lymphocytic Leukemia
Fixed-Duration Venetoclax Plus Rituximab Confers Benefit in Chronic Lymphocytic Leukemia
Fixed-duration venetoclax plus rituximab provides sustained, durable response for patients with relapsed chronic lymphocytic leukemia.
Combined Venetoclax, Obinutuzumab vs Chlorambucil, Obinutuzumab for Chronic Lymphocytic Leukemia
Venetoclax plus obinutuzumab appears to yield good responses for a limited duration among patients with previously untreated CLL.
Triple Therapy for CLL Shows Promise in Phase 2 Trial
Most patients achieved deep remission after a 14-month regimen of obinutuzumab, ibrutinib, and venetoclax.
Uncommon Mutation in CLL Associated With More Favorable Prognostic Factors
Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who had an L265P MYD88 mutation were uncommon and had distinct features.
Risk-Adapted Bendamustine and Rituximab: An Alternative for Older Individuals With CLL
Risk-adapted dosing of bendamustine and rituximab may be beneficial and tolerable for elderly patients with CLL, a retrospective study found.
Targeted Molecular Therapies for the Treatment of Chronic Lymphocytic Leukemia
Researchers reviewed promising advances in therapy options for patients with CLL and the challenges associated with these new treatments.
Can Culturing CAR T Cells With Ibrutinib Improve Their Efficacy in CLL?
Sustained remission of CLL is associated with enrichment of a less-differentiated, early-memory phenotype of T cells in the apheresis product used to make CAR-T therapies.
Prior Use of Novel Agents Does Not Affect alloHCT Outcomes in CLL
Prior treatment with at least 1 novel agent did not affect allogeneic transplant outcomes among patients with CLL.
CLL Diagnosis Preceded by Decades of Increased Infection Susceptibility
Infections often precede a formal diagnosis of CLL. Researchers found that antimicrobial use began to rise 6 years prior to CLL diagnosis.
-
Loading...
-
Loading...
Next post in Leukemia
